RAPT Q4 2019 Earnings Report
Key Takeaways
RAPT Therapeutics reported a net loss of $13.2 million for the fourth quarter of 2019, compared to a net loss of $9.4 million for the fourth quarter of 2018. Research and development expenses for the fourth quarter of 2019 were $10.2 million, compared to $8.4 million for the same period in 2018.
Net loss for the fourth quarter of 2019 was $13.2 million, compared to $9.4 million for the fourth quarter of 2018.
Research and development expenses for the fourth quarter of 2019 were $10.2 million, compared to $8.4 million for the same period in 2018.
General and administrative expenses for the fourth quarter of 2019 were $2.6 million, compared to $1.3 million for the same period in 2018.
As of December 31, 2019, the company had cash and cash equivalents of $77.4 million.